Health Care Equipment

BIOLASE INC

BIOLASE INC released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 32,536,000 USD and EPS of -0.4848

BIOLASE INC released FY2024 Q3 earnings on November 7, 2024 (EST), actual revenue $10.85M (forecast $10.9M), actual EPS -0.0376

BIOLASE INC released FY2023 Cumulative 3Q earnings on August 8, 2024 (EST), with actual revenue of 35.67M USD and EPS of -58.7012

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

The Global Luminex Multiplex Assays Market is projected to grow from USD 1.82 billion in 2025 to USD 3.89 billion by 2033, at a CAGR of 10.0%. This growth is driven by the rising demand for high-throughput biomarker profiling and standardized testing workflows. Key factors include the efficiency of multiplex systems, regulatory support for standardized panels, and the expansion of outsourced research models. However, challenges such as validation complexity and elevated costs may impact adoption rates.

fidelity

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

BIOLQ

MDLB

BioLab Holdings has earned the Great Place to Work® certification, reflecting its commitment to a positive workplace culture based on employee feedback. Key findings include 90% of employees feeling treated fairly, 96% affirming physical safety, and 92% confident in service quality. The certification highlights BioLab's focus on inclusion, transparency, and ethical leadership, positioning it as an employer of choice in the life sciences sector. The company plans to continue improving through employee insights and regular feedback surveys.

prnewswire

Medlab Clinical Ltd.

15:05 ETBioLab Holdings Earns Great Place to Work® Certification

BIOLASE INC(BIOLQ.US)

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

15:05 ETBioLab Holdings Earns Great Place to Work® Certification